Results 1 to 10 of about 108,162 (269)

Individualized pharmacotherapy: background and development. [PDF]

Ann Transl Med
Jørgensen JT, Westergaard N.
europepmc   +1 more source

Age, Rather Than Social Vulnerability, Is Associated With Disparities in Prescription Patterns in Inflammatory Bowel Disease: An Epic Cosmos Study. [PDF]

Gastro Hep Adv
Zuercher H, Potlach T, Sinha M, Baskaran N, Bidani SS, Olson S, Jiao T, Zimmermann EM, Chaudhry NA.   +8 more
europepmc   +1 more source

Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma. [PDF]

Pulm Ther
de Miguel-Díez J, Callejas-González FJ, Blanco-Aparicio M, Cosío BG, González-Villaescusa C, Santos S, Cabrera C.   +6 more
europepmc   +1 more source

Pre-clinical development of an enzyme replacement therapy (CPI-601) for CLN1 Batten disease: process development, stability and uptake studies in different species

Neurotherapeutics
Renuka Raman, Ph.D., Ben Horst, Ph.D., Maryam Zare, Ph.D., Zahra Shajrokh, Magdalena Leszczyniecka, Ph.D., Sean Ekins, Ph.D., D.Sc   +5 more
doaj   +1 more source

Use of cells and/or biologics combined with scaffolds for soft tissue regeneration around dental implants. [PDF]

J Periodontol
Montero E, Chen Z, Sánchez N, Sanz Esporrin J, Wang HL, Mandelaris GA.   +5 more
europepmc   +1 more source

Early Intervention With Biologics for Asthma Remission: Promising or Premature? [PDF]

Respirology
Nolasco S, Bernaola J, Nair P.
europepmc   +1 more source

The Impact of Psoriasis Treatment on Depression and Suicide Risk: A Systematic Review. [PDF]

Depress Anxiety
Shahsavaripoor B, Karami S, Sahebi A, Jafferany M.   +3 more
europepmc   +1 more source

Low compliance and polypharmacy as key negative predictors in highly effective anti-psoriatic treatments. [PDF]

J Eur Acad Dermatol Venereol
Damiani G.
europepmc   +1 more source

Real-World Patterns of Immunomodulator Use in Patients with Inflammatory Bowel Disease Receiving Biologic Therapy Under a 54-Week Reimbursement Cap: A 12-Year Retrospective Single-Center Cohort from Taiwan. [PDF]

J Inflamm Res
Lin WC, Chang CW, Wang HY, Hsu TC, Chang CW.   +4 more
europepmc   +1 more source

Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same. [PDF]

BioDrugs
Park JP, Oh H, Woollett GR.
europepmc   +1 more source